Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

0.4500 -0.0300 (-6.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 Next >
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
From SciSparc Ltd
Via Globe NewsWire
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via Globe NewsWire
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
From SciSparc Ltd
Via Globe NewsWire
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
From SciSparc Ltd
Via Globe NewsWire
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
From SciSparc Ltd
Via Globe NewsWire
Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million
From Jeffs' Brands Ltd
Via Globe NewsWire
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
From SciSparc Ltd
Via Globe NewsWire
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
Clearmind Medicine submitted patent applications to protect the novel compounds 
From SciSparc Ltd
Via Globe NewsWire
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via Globe NewsWire
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
From SciSparc Ltd
Via Globe NewsWire
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
From SciSparc Ltd
Via Globe NewsWire
Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
From Clearmind Medicine Inc.
Via Globe NewsWire
SciSparc Announces Corporate Restructuring plan
From SciSparc Ltd
Via Globe NewsWire
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
From SciSparc Ltd
Via Globe NewsWire
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
From SciSparc Ltd
Via Globe NewsWire
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
From SciSparc Ltd
Via Globe NewsWire
SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center
From SciSparc Ltd
Via Globe NewsWire
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
From SciSparc Ltd
Via Globe NewsWire
SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand
From SciSparc Ltd
Via Globe NewsWire
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
From SciSparc Ltd
Via Globe NewsWire
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
From SciSparc Ltd
Via Globe NewsWire
SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line
From SciSparc Ltd
Via Globe NewsWire
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
From SciSparc Ltd
Via Globe NewsWire
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
From SciSparc Ltd
Via Globe NewsWire
SciSparc: Wellution™ Signs an Agreement with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms
From SciSparc Ltd
Via Globe NewsWire
SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days
From SciSparc Ltd
Via Globe NewsWire
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via Globe NewsWire
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
From SciSparc Ltd
Via Globe NewsWire
Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.
NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... 
From Traders News Source
Via AccessWire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.